Searches for rare or forbidden semileptonic charm decays

We present searches for rare or forbidden charm decays of the form $X_c^+\to h^\pm\ell^\mp\ell^{(\prime)+}$, where $X_c^+$ is a charm hadron ($D^+$, $D^+_s$, or $\Lambda_c^+$), $h^\pm$ is a pion, kaon, or proton, and $\ell^{(\prime)\pm}$ is an electron or muon. The analysis is based on $384 fb^{-1}$ of $e^+e^-$ annihilation data collected at or close to the $\Upsilon(4S)$ resonance with the BaBar detector at the SLAC National Accelerator Laboratory. No significant signal is observed for any of the 35 decay modes that are investigated. We establish 90% confidence-level upper limits on the branching fractions between $1 \times 10^{-6}$ and $44 \times 10^{-6}$ depending on the channel. In most…

Study of radiative bottomonium transitions using converted photons

We use 111+/-1 million Upsilon(3S) and 89+/-1 million Upsilon(2S) events recorded by the BaBar detector at the PEP-II B-factory at SLAC to perform a study of radiative transitions between bottomonium states using photons that have been converted to e+e- pairs by the detector material. We observe Upsilon(3S) -> gamma chi_b0,2(1P) decay, make precise measurements of the branching fractions for chi_b1,2(1P,2P) -> gamma Upsilon(1S) and chi_b1,2(2P) -> gamma Upsilon(2S) decays, and search for radiative decay to the eta_b(1S) and eta_b(2S) states.

Search for Low-Mass Dark-Sector Higgs Bosons

See paper for full list of authors - 7 pages, 5 postscript figures, submitted to Phys. Rev. Lett; Recent astrophysical and terrestrial experiments have motivated the proposal of a dark sector with GeV-scale gauge boson force carriers and new Higgs bosons. We present a search for a dark Higgs boson using 516 fb-1 of data collected with the BABAR detector. We do not observe a significant signal and we set 90% confidence level upper limits on the product of the Standard Model-dark sector mixing angle and the dark sector coupling constant.

Methods, kits and means for determining intracellular interactions

Methods, kits and systems for determining whether a reaction occurs between a chimeric transmembrane receptor and an intracellular interaction partner thereof within a cell.

PD-8 Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY)